AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01681381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Firebird2® DES
Description: The Firebird2® rapamycin-eluting stent (Firebird2® DES) is an open cell balloon expandable cobalt chromium stent coated with a biocompatible durable styrene-butylenes-styrene (SBS) polymer containing rapamycin at a dose of 9 micrograms per millimeter of stent length. In vitro assays have shown that about 50% of the drug elutes in 1 week and approximately 90% elutes in 1 month. This stent is supplied pre-mounted on a delivery catheter and is available in the following sizes: lengths of 13, 18, 23, 29, 33 mm and diameters of 2.25, 2.5, 2.75, 3.0, 3.5, 4.0 mm.
Study NCT02925351 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT scan
Study NCT02925351 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 Clofarabine
Description: Given IV
Study NCT02925351 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan
Study NCT06217874 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study NCT00816751 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paracervical block
Description: The paracervical block was administered using 20 ml of buffered lidocaine and a 5/8 inch, 25-gauge needle. A small amount was injected at the tenaculum site, and the remainder equally distributed around the cervicovaginal junction at 3, 5, 7, and 9 o'clock. The depth was standardized at 5/8 inch by inserting the needle to the hub.
Study NCT00816751 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracervical
Description: The intracervical block was administered using 20 ml of buffered lidocaine and a 1-1/2 inch, 20 gauge needle in order to overcome the increased resistance to injection caused by the cervical stroma. A small amount was injected at the tenaculum site, and the remainder into the cervical stroma at 12, 3, 6, and 9 o'clock, at a depth of 1-1/2 inch by inserting the needle to the hub.
Study NCT00816751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buffered Lidocaine, vasopressin, sodium bicarbonate
Description: The buffered lidocaine preparation for both block techniques consisted of 50 mL of 1% lidocaine, 5 units of vasopressin, and 5 mL 8% sodium bicarbonate.
Study NCT00816751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buffered Lidocaine, vasopressin, sodium bicarbonate
Description: The buffered lidocaine preparation for both block techniques consisted of 50 mL of 1% lidocaine, 5 units of vasopressin, and 5 mL 8% sodium bicarbonate.
Study NCT04738058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bovine Lactoferrin Supplement
Description: Bovine lactoferrin or placebo will be given to both arms with each feed for 30 days or till discharge from NICU the Lactoferrin dose 100mg/day Then determin is effect by serum zonulin level
Study NCT04738058 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT02708069 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: e-Unstuck
Description: An e-learning software that delivers the evidence-based Executive Functioning intervention to parents of children with Autism Spectrum Disorder without Intellectual Disability (ASDwoID) with personalized training and feedback on the evidence-based Unstuck and On Target (UOT) curriculum. Through video modeling, intelligent games, adaptive interactive exercises, and personalized feedback, e-Unstuck will provide parents with new tools for applying UOT principles to real world settings, above and beyond learning UOT principles.
Study NCT02708069 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Unstuck and On Target
Description: An executive functioning intervention specifically targeted to the needs of the Autism Spectrum Disorder without Intellectual Disability (ASDwoID) population.
Study NCT04693130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based prenatal education
Description: Mindfulness-based prenatal education involves mindfulness breathing and other skills with mindfulness meditations.
Study NCT04693130 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Hospital-based antenatal care
Description: Hospital-based antenatal care involves all aspects of pregnancy, childbirth and postpartum.
Study NCT01292252 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: teriparatide
Description: Teriparatide 20 ug subcutaneous injection daily for 12 weeks
Study NCT01292252 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution
Study NCT02267967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfatinib
Description: Sulfatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle.
Study NCT01580319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical exercise
Description: 150 minutes per week
Study NCT01171625 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Implantation of CEP Magna Ease Model 3300TFX
Description: Heart Valve Surgery
Study NCT02071836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Right Turns web application
Study NCT03738176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone in orabase
Description: triamcinolone 140 gm-Na CMC 50 gm
Study NCT02071836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Study NCT04612517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZP7570
Description: Each subject will be randomly allocated to multiple doses of ZP7570 at one of four dose levels in each cohort.
Study NCT04612517 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo; corresponding volume
Study NCT04283916 — intervention group
Intervention type: DRUG
Intervention: Botulinum Toxins
Description: Botulinum toxin injection to abdominal wall
Study NCT02981628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02981628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or SC
Study NCT02981628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging
Description: Undergo imaging
Study NCT02981628 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Given IV
Study NCT03267420 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: BpTRU First, Unattended Omron Second
Description: Visit 1: The participants will have the oscillometric device, BpTRU applied to their arm with the higher blood pressure. This will allow assessment with the commonest used Canadian device, which provides an average after 5 unattended readings. This assessment will be followed by the participant wearing a 24 hour ambulatory blood pressure monitor (ABPM) for 24 hours.~Visit 2: Upon returning the 24 hour ABPM device, the patient will have their blood pressure measured with an unattended Omron second. The Omron HEM 907XL will be applied to the same arm that the BpTRU was applied to in the first visit. There will be 5 minutes of quiet rest (participant alone) and three readings subsequently while the patient is still alone with the average blood pressure measurement being noted.
Study NCT03267420 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Unattended Omron First, BpTRU Second
Description: Visit 1: The participants will have the Omron HEM 907XL will be applied to their arm with the higher blood pressure. There will be 5 minutes of quiet rest (participant alone) and three readings subsequently while the patient is still alone with the average blood pressure measurement being noted.This assessment will be followed by the participant wearing a 24 hour ambulatory blood pressure monitor (ABPM) for 24 hours.~Visit 2: Upon returning the 24 hour ABPM device, the participants will have the oscillometric device, BpTRU applied to the same arm that the Omron HEM 907 XL was applied to in the first visit. This will allow assessment with the commonest used Canadian device, which provides an average after 5 unattended blood pressure readings.
Study NCT03267420 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Partially Attended Omron First, Unattended Omron Second
Description: Visit 1: The participant will have the Omron HEM 907 XL applied to the arm with the higher blood pressure. There will be five minutes of quiet rest (patient alone) and three reading subsequently, but with the nurse entering the room (i.e., partially attended), with the average being noted. This assessment will be followed by the participant wearing a 24 hour ambulatory blood pressure monitor (ABPM) for 24 hours.~Visit 2: Upon returning 24 hour ABPM device, the participant will have the Omron HEM 907 XL applied to same arm that was used during the first visit. There will be five minutes of quiet rest (patient alone) and three readings subsequently (patient still alone) with the average blood pressure measurement being noted.
Study NCT03866915 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Aortic pulse wave velocity measurement
Description: Aortic pulse pulse wave velocity (AoPWV) measured by photoplethysmography
Study NCT03866915 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 6 minutes walking test
Description: This test is performed routinely in the pre-rehabilitation units or in external anesthesiology consultations during the preoperative visit. In essence, it consists in measuring the maximum distance the patient is able to walk in 6 minutes, in a short walk in a corridor, simultaneously assessing the heart rate, oxygen saturation and the degree of dyspnea. In general, healthy people can walk between 400 and 700 meters in 6 minutes, depending on age, height and sex.
Study NCT00593502 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The dosage of placebo will be similar to the active drug
Study NCT03238976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nature sounds
Description: Nature sounds will be played for patients in the nature sounds exposure group.
Study NCT02981628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given PO or IV
Study NCT02981628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture
Study NCT02981628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT
Study NCT02981628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV or IM
Study NCT02981628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study NCT02071836 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Study NCT04756245 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participants in this arm participate in 4 group-based behavioral counseling sessions plus 8 one-on-one coaching session within virtual reality software. Participants aim to engage in approximately 150 minutes per week of moderate-to-vigorous activity, with options including both virtual reality and real-world physical activities.
Study NCT03725852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1205
Description: GLPG1205 will be provided as an oral hard gelatin capsule.
Study NCT03609424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001, Imatinib
Description: -Phase Ib part~: The standard 3+3 dose escalation scheme will be applied. DLTs will be evaluated during the first cycle (4 weeks).~PDR001 400mg, every 4 weeks, IV~Imatinib dose level -1 : 200mg, PO, QD Imatinib dose level 1 : 300mg, PO, QD Imatinib dose level 2 : 400mg, PO, QD~-Phase II part~* Recommended dose defined in phase Ib part will be tested
Study NCT01820000 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diffusion Weighted Imaging with MRI scans
Description: Subjects will have an MRI(magnetic resonance imaging)performed. This sequence will take no longer than 10 to 15 minutes to complete. Only DWI (diffusion weighted imaging) will be added to the standard cardiac MR protocol for viability which requires contrast injection. DWI(diffusion weighted imaging) sequence does not require contrast injection.
Study NCT00506142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marqibo® (vincristine sulfate liposomes injection)
Description: Cohort 1 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every 2 weeks.~Cohort 2 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every week.
Study NCT02345239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: proton pump inhibitor
Study NCT02213250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BENEFIX
Description: Single dose of 50 IU/kg of BeneFIX by intravenous infusion within 10 minutes.
Study NCT04756245 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Conference
Description: Participants in this arm participate in 4 group-based behavioral counseling sessions plus 8 one-on-one coaching session within video conference software. Participants aim to engage in approximately 150 minutes per week of moderate-to-vigorous activity, with options including both streaming video and real-world physical activities.
Study NCT01689090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COX inhibitor
Description: Administration of 1 drop voltaren 45 minutes before recordings of diameter changes of retinal vessels are initiated
Study NCT03725852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: GLPG1205 matching placebo will be provided as an oral hard gelatin capsule.
Study NCT04552002 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic group
Description: Probiotics and prebiotics
Study NCT03112876 — intervention group
Intervention type: OTHER
Intervention: Skin Surface Lipid Collection and Skin Barrier Function
Description: All five groups will undergo the same study intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
Study NCT00182143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LMWH (Fragmin, dalteparin)
Description: Placebo AM dose (normal saline) and LMWH (Fragmin, dalteparin) 5000IU PM dose
Study NCT00182143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated Heparin
Description: 5000 IU BID
Study NCT01689090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L-NG-monomethyl arginine citrate
Description: Intravenous administration of L-NMMA during recordings of diameter changes of retinal vessels
Study NCT02300233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volanesorsen
Description: 300 mg volanesorsen administered subcutaneously once-weekly for 26 weeks.
Study NCT02300233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volanesorsen-matching placebo administered subcutaneously once-weekly for 26 weeks.
Study NCT03745950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Oral Capsule
Description: - Olaparib will be administrated by oral at dose of 300 mg twice daily during the induction period and in maintenance
Study NCT03745950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: - Placebo will be administrated by oral at dose of 300 mg twice daily during the induction period and in maintenance
Study NCT04326452 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bidirectional oxygenation mouthpiece
Description: Use of our bidirectional oxygenation mouthpiece with conventional oxygen support.
Study NCT04089514 — intervention group
Intervention type: DRUG
Intervention: Adalimumab
Description: Administered as specified in the treatment arm
Study NCT03212352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Adding 600 mg of Mifepristone to the regular treatment with Misoprostol 800 mcg.
Study NCT03212352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: Regular treatment with Misoprostol 800 mcg.
Study NCT03212352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Regular treatment with Misoprostol 800 mcg.
Study NCT04670809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevidipine Butyrate Injection
Description: Initiate the intravenous infusion of Clevidipine Butyrate Injection at 2 mg/hour. The dose should be doubled every 3 minutes in the first 30 minutes if the desired blood pressure reduction (≥15% and ≤25%) is not achieved and the maximum dose is 32 mg/hour. The infusion duration should be at least 12 hours and less than 72 hours. Oral antihypertensive drugs should be given at about 2 hours before stopping infusion.
Study NCT04670809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ncardipine Hydrochloride Injection
Description: Dilute the Ncardipine Hydrochloride Injection to 0.1mg/ml. Initiate the intravenous infusion at 0.5μg/(kg•min). A 0.5-1μg/(kg•min) dose should be added every 3 minutes in the first 30 minutes if the desired blood pressure reduction (≥15% and ≤25%) is not achieved and the maximum dose is 6μg/(kg•min). The infusion duration should be at least 12 hours and less than 72 hours. Oral antihypertensive drugs should be given at about 2 hours before stopping infusion.
Study NCT02746302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20004
Study NCT02746302 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00427193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric Restriction (CR)
Description: Participants follow a diet with 25% fewer calories than calculated at baseline over a period of 24 months
Study NCT01689090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COX inhibitor + L-NG-monomethyl arginine citrate
Description: Combination of interventions. Administration of an eye drop voltaren and 45 minutes later infusion with L-NMMA is started and recording of diameter changes of retinal vessels is performed
Study NCT03675581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon
Description: fixed sequence trial
Study NCT03675581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: fixed sequence trial
Study NCT03557008 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabies Vaccine
Description: A 1.0 milliliter (mL) dose of Imovax® will be given to participants on Day 0 and Day 28 of the study.
Study NCT03557008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: The antibiotic regimen will be given for five days beginning 3 days prior to vaccination, on the vaccination day, and one day after vaccination for a total for 5. The regimen will include 500 milligrams (mg) of Flagyl taken by mouth three times a day.
Study NCT03557008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: The antibiotic regimen will be given for five days beginning 3 days prior to vaccination, on the vaccination day, and one day after vaccination for a total for 5. The regimen will include 125 mg of Vancocin taken by mouth four times a day.
Study NCT03557008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neomycin Sulfate
Description: The antibiotic regimen will be given for five days beginning 3 days prior to vaccination, on the vaccination day, and one day after vaccination for a total for 5. The regimen will include 500 milligrams (mg) of Neomycin sulfate taken by mouth three times a day.
Study NCT00731497 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Solar Water Disinfection (SODIS)
Description: Intervention group has SODIS implemented at the household level as a way to disinfect drinking water
Study NCT00269789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritalin
Study NCT00427193 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants continue their current diet for 24 months
Study NCT00269789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS Methylphenidate HCl
Study NCT00269789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00296361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: immunosuppression
Study NCT00748631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balloon kyphoplasty
Description: A bilateral approach is chosen to insert working cannulas into the posterior part of the vertebral body through a posterior transpedicular approach.Once inserted, the balloons are inflated using visual, volume and pressure control to create a cavity.The balloons are then deflated and removed. The Bone Filler Device is then advanced through the working cannula towards the anterior part of the cavity and cement is slowly extruded by a stainless steel stylet, acting as a plunger. When the amount of cement from the first Bone Filler Device is delivered in the cavity, it is removed and another Bone Filler Device is advanced through the working cannula.
Study NCT00818194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended release tacrolimus
Description: oral
Study NCT00818194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine A microemulsion
Description: oral